These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 35795828)

  • 1. The Safety and Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Study.
    Yin GQ; Li ZL; Li D
    Cancer Manag Res; 2022; 14():2133-2141. PubMed ID: 35795828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemoradiotherapy with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma.
    Chen F; Qiu L; Mu Y; Sun S; Yuan Y; Shang P; Ji B; Wang Q
    Front Surg; 2022; 9():893372. PubMed ID: 35983558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study.
    Yang P; Zhou X; Yang X; Wang Y; Sun T; Feng S; Ma X
    World J Surg Oncol; 2021 Nov; 19(1):333. PubMed ID: 34809658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study).
    Yang Y; Zhang J; Meng H; Ling X; Wang X; Xin Y; Jiang H; Zhang L; Fang C; Liang H; Ma J; Zhu J
    Int J Surg; 2024 Mar; 110(3):1430-1440. PubMed ID: 38051925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study.
    Zhou RQ; Luo J; Li LJ; Du M; Wu QC
    BMC Surg; 2023 May; 23(1):114. PubMed ID: 37161374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma.
    Liu J; Yang Y; Liu Z; Fu X; Cai X; Li H; Zhu L; Shen Y; Zhang H; Sun Y; Chen H; Yu B; Zhang R; Shao J; Zhang M; Li Z
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. M1 macrophage predicted efficacy of neoadjuvant camrelizumab combined with chemotherapy vs chemotherapy alone for locally advanced ESCC: A pilot study.
    Wang S; Xu G; Li M; Zheng J; Wang Y; Feng X; Luo J; Wang S; Liu H; Duan W; Zhang H; Huang D; Zhao F; Nie Y; Yang J
    Front Oncol; 2023; 13():1139990. PubMed ID: 36969032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial.
    Yang G; Su X; Huang Y; Luo G; Wang Z; Cai P; Zheng Y; Bei T; Huang M; Bai Y; He H; Xiang J; Cai M; Zhong J; Guo Q; Zhang X
    J Transl Med; 2023 Jun; 21(1):411. PubMed ID: 37355621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study.
    Xia P; Li P; Wu S; Wang Y; Ye P; Zhang C; Hu J; Kidane B; Lampridis S; Velotta JB; Wakefield CJ; Zhu L; Wang L
    Ann Transl Med; 2022 Sep; 10(18):991. PubMed ID: 36267734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma.
    Yang G; Su X; Yang H; Luo G; Gao C; Zheng Y; Xie W; Huang M; Bei T; Bai Y; Wang Z; Cai P; He H; Xiang J; Cai M; Zhang Y; Qu C; Fu J; Liu Q; Hu Y; Zhong J; Huang Y; Guo Q; Zhang X
    Ann Transl Med; 2021 Aug; 9(15):1254. PubMed ID: 34532391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery affect outcomes for locally advanced esophageal squamous cell carcinoma?
    Liu J; Zhu L; Huang X; Lu Z; Wang Y; Yang Y; Ye J; Gu C; Lv W; Zhang C; Hu J
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):161. PubMed ID: 38536527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose chemotherapy sensitizes locally advanced esophageal squamous cell carcinoma to PD-1 blockade for a higher pathological complete response rate and survival.
    Wang P; Lei M; Weng G; Huang R; Lin H; Wei W; Chen Y; He H; Chen P; Zhang D; Chen W; Zhou H; Gao P; Liu S; Wang F
    Transl Oncol; 2023 Oct; 36():101736. PubMed ID: 37478670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study.
    Liu J; Li J; Lin W; Shao D; Depypere L; Zhang Z; Li Z; Cui F; Du Z; Zeng Y; Jiang S; He P; Gu X; Chen H; Zhang H; Lin X; Huang H; Lv W; Cai W; Liang W; Liang H; Jiang W; Wang W; Xu K; Cai W; Wu K; Lerut T; Fu J; He J
    Int J Cancer; 2022 Jul; 151(1):128-137. PubMed ID: 35188268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety, and survival of neoadjuvant immunotherapy plus chemotherapy in locally advanced esophageal squamous cell carcinoma: A real-world retrospective study.
    Guo Y; Xu X; Wang T; Liu Y; Gu D; Fang Y; Wang Q; Shi H; Wu D; Zhang Z; Zhou G; Ye J
    Int Immunopharmacol; 2024 Sep; 138():112558. PubMed ID: 38941666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study).
    Yang Y; Zhu L; Cheng Y; Liu Z; Cai X; Shao J; Zhang M; Liu J; Sun Y; Li Y; Yi J; Yu B; Jiang H; Chen H; Yang H; Tan L; Li Z
    BMC Cancer; 2022 May; 22(1):506. PubMed ID: 35524205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma.
    Lv H; Tian Y; Li J; Huang C; Sun B; Gai C; Li Z; Tian Z
    Front Oncol; 2022; 12():864533. PubMed ID: 35574384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy.
    Qiao Y; Zhao C; Li X; Zhao J; Huang Q; Ding Z; Zhang Y; Jiao J; Zhang G; Zhao S
    Front Immunol; 2022; 13():953229. PubMed ID: 35911723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCC.
    Li Y; Zhou A; Liu S; He M; Chen K; Tian Z; Li Y; Qin J; Wang Z; Chen H; Tian H; Yu Y; Qu W; Xue L; He S; Wang S; Bie F; Bai G; Zhou B; Yang Z; Huang H; Fang Y; Li B; Dai X; Gao S; He J
    BMC Med; 2023 Mar; 21(1):86. PubMed ID: 36882775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer.
    Hou X; Shi X; Luo J
    Oncol Lett; 2022 Jul; 24(1):215. PubMed ID: 35720491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of camrelizumab-containing neoadjuvant therapy in patients with esophageal squamous cell carcinoma: a prospective multicenter observational cohort study.
    Zhang Y; Shen G; Xu R; Huang G; Huang Z; Duan H; Yang S; Zheng Q; Yang L; Liu R; Ma L; Chen S; Yi Y; Zhang Z; Li K; Birdas TJ; Koyanagi K; Simone CB
    J Thorac Dis; 2023 Nov; 15(11):6228-6237. PubMed ID: 38090323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.